Drug
GM Csf Naxitamab
GM Csf Naxitamab: highest development phase Phase 2, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| GM-CSF + Naxitamab NCT03363373 | Phase 2 | Neuroblastoma |
Latest
No recent events.
Follow GM Csf Naxitamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.